What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Mallat, Samir G ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Amlodipine; Angiotensin receptor ii blocker; Diabetes mellitus; Hydrochlorothiazide; Hypertension; Renal impairment; Single pill combination; Telmisartan

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZELNIDIPINE; AZILSARTAN; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CREATININE; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; EDEMA; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; METABOLIC DISORDER; MICROALBUMINURIA; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RENAL PROTECTION; REVIEW; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT;

ANGIOTENSIN RECEPTOR ANTAGONISTS; BLOOD PRESSURE; COMORBIDITY; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION;

EID: 84859481728     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-32     Document Type: Review

References (129)

1. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010, 303(20):2043-2050. 10.1001/jama.2010.650, 20501926.
2. Ezzati M, Oza S, Danaei G, Murray CJ. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation 2008, 117(7):905-914. 10.1161/CIRCULATIONAHA.107.732131, 18268146.
3. Ostchega Y, Dillon CF, Hughes JP, Carroll M, Yoon S. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007, 55(7):1056-1065. 10.1111/j.1532-5415.2007.01215.x, 17608879.
4. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of NICE guidance. BMJ 2011, 343:d4891. 10.1136/bmj.d4891, 21868454.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42(6):1206-1252. 10.1161/01.HYP.0000107251.49515.c2, 14656957.
6. Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De CR, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, Van ZP, Waeber B, Williams B. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25(6):1105-1187. 10.1097/HJH.0b013e3281fc975a, 17563527.
7. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clement D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009, 27(11):2121-2158. 10.1097/HJH.0b013e328333146d, 19838131.
8. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009, 32(1):3-107.
9. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008, 8(1):45-50. 10.2165/00129784-200808010-00006, 18303937.
10. Frank J. Managing hypertension using combination therapy. Am Fam Physician 2008, 77(9):1279-1286.
11. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007, 120(8):713-719. 10.1016/j.amjmed.2006.08.033, 17679131.
12. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010, 55(2):399-407. 10.1161/HYPERTENSIONAHA.109.139816, 20026768.
13. Zeng F, Patel BV, Andrews L, Frech-Tamas F, Rudolph AE. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin 2010, 26(12):2877-2887. 10.1185/03007995.2010.534129, 21067459.
14. NICE Guidelines: Management of hypertension in adults in primary care. 2011. 2011,
15. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360(9349):1903-1913.
16. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326(7404):1427. 10.1136/bmj.326.7404.1427, 162261, 12829555.
17. Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin 2008, 24(8):2389-2401. 10.1185/03007990802262457, 18616863.
18. Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin 2008, 24(4):1039-1047. 10.1185/030079908X280581, 18307835.
19. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009, 30(5):418-424. 10.1159/000237742, 19738369.
20. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009, 122(3):290-300. 10.1016/j.amjmed.2008.09.038, 19272490.
21. Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. Vasc Health Risk Manag 2008, 4(3):653-664. 2515425, 18827915.
22. Bohm M, Thoenes M, Danchin N, Bramlage P, La PP, Volpe M. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens 2007, 25(11):2317-2324. 10.1097/HJH.0b013e3282ef1c5f, 17921828.
23. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Clin Hypertens (Greenwich ) 2011, 13(3):146-154.
24. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH, Hall WD, Jones WE, Kountz DS, Lea JP, Nasser S, Nesbitt SD, Saunders E, Scisney-Matlock M, Jamerson KA. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 2010, 56(5):780-800. 10.1161/HYPERTENSIONAHA.110.152892, 20921433.
25. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321(7274):1440-1444. 10.1136/bmj.321.7274.1440, 27545, 11110735.
26. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372(9638):547-553. 10.1016/S0140-6736(08)61236-2, 18707986.
27. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349(20):1893-1906. 10.1056/NEJMoa032292, 14610160.
28. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif PC, Smith BA, Dahlof B. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119(4):530-537. 10.1161/CIRCULATIONAHA.108.826214, 19153265.
29. Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JF. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011, 123(10):1098-1107. 10.1161/CIRCULATIONAHA.110.964171, 21357827.
30. Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med 2010, 123(11):1016-1030. 10.1016/j.amjmed.2010.06.014, 21035591.
31. Weber MA, Messerli FH. Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension 2008, 51(6):1465-1467. 10.1161/HYPERTENSIONAHA.108.111393, 18413486.
32. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358(15):1547-1559.
33. Lacourciere Y. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. Clin Ther 2000, 22(10):1213-1224. 10.1016/S0149-2918(00)83064-7, 11110232.
34. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372(9644):1174-1183.
35. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, Cesana G, Mancia G. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008, 26(4):819-824. 10.1097/HJH.0b013e3282f4edd7, 18327094.
36. Kjeldsen SE, Os I, Hoieggen A, Beckey K, Gleim GW, Oparil S. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs 2005, 5(1):17-22. 10.2165/00129784-200505010-00003, 15631534.
37. Littlejohn TW, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R, Oigman W. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 × 4 factorial study. Postgrad Med 2009, 121(2):5-14. 10.3810/pgm.2009.03.1972, 19641263.
38. Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011, 124(2):128-135. 10.1016/j.amjmed.2010.08.007, 21295192.
39. Oparil S, Weber M. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy. Postgrad Med 2009, 121(2):25-39. 10.3810/pgm.2009.03.1974, 19494475.
40. Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007, 29(4):563-580. 10.1016/j.clinthera.2007.03.018, 17617280.
41. Fletcher A, Bulpitt C. Quality of life in the treatment of hypertension. The effect of calcium antagonists. Drugs 1992, 44(Suppl 1):135-140.
42. Pedrinelli R, Dell'Omo G, Mariani M. Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. J Hum Hypertens 2001, 15(7):455-461. 10.1038/sj.jhh.1001201, 11464254.
43. de la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens 2009, 23(8):503-511. 10.1038/jhh.2008.157, 19148104.
44. Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011, 124(2):128-135. 10.1016/j.amjmed.2010.08.007, 21295192.
45. Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, Preti P. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens 2006, 20(3):177-185. 10.1038/sj.jhh.1001964, 16306998.
46. Gosse P, Neutel JM, Schumacher H, Lacourciere Y, Williams B, Davidai G. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Blood Press Monit 2007, 12(3):141-147. 10.1097/MBP.0b013e3280b10bbd, 17496463.
47. Lacourciere Y, Neutel JM, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006, 19(1):104-112. 10.1016/j.amjhyper.2005.10.001, 16461201.
48. Nalbantgil I, Nalbantgil S, Ozerkan F, Yilmaz H, Gurgun C, Zoghi M, Aytimur M, Onder R. The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension. Int J Clin Pract Suppl 2004, 145:50-54.
49. Ragot S, Ezzaher A, Meunier A, Poterre M, Bourkaib R, Herpin D. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens 2002, 16(12):865-873. 10.1038/sj.jhh.1001494, 12522468.
50. Williams B, Gosse P, Lowe L, Harper R. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006, 24(1):193-200. 10.1097/01.hjh.0000194364.11516.ab, 16331118.
51. Nishida Y, Takahashi Y, Nakayama T, Soma M, Asai S. Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study. Cardiovasc Diabetol 2011, 10:74. 10.1186/1475-2840-10-74, 3163179, 21827713.
52. Nishida Y, Takahashi Y, Nakayama T, Soma M, Kitamura N, Asai S. Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. Cardiovasc Diabetol 2010, 9:38. 10.1186/1475-2840-9-38, 2933671, 20712859.
53. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010, 11(7):627-636. 10.1016/S1470-2045(10)70106-6, 20542468.
54. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens 2011, 29(4):623-635.
55. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011, 12(1):65-82. 10.1016/S1470-2045(10)70260-6, 21123111.
56. Izzo JL, Zion AS. Value of Angiotensin receptor blocker therapy in diabetes. J Clin Hypertens (Greenwich ) 2011, 13(4):290-295.
57. American Diabetes Association Standards of medical care in diabetes. Diabetes Care 2008, 31(Suppl 1):12-54. American Diabetes Association.
58. Trimarchi H. Role of aliskiren in blood pressure control and renoprotection. Int J Nephrol Renovasc Dis 2011, 4:41-48. 3108787, 21694948.
59. Parving HH, Brenner BM, McMurray JJ, de ZD, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009, 24(5):1663-1671. 10.1093/ndt/gfn721, 19145003.
60. Chrysant SG, Chrysant GS. Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opin Pharmacother 2004, 5(3):657-667. 10.1517/14656566.5.3.657, 15013933.
61. Flack JM. Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide. Int J Clin Pract 2007, 61(12):2093-2102. 10.1111/j.1742-1241.2007.01577.x, 2228392, 17887997.
62. Lacourciere Y, Poirier L, Hebert D, Assouline L, Stolt P, Rehel B, Khder Y. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005, 27(7):1013-1021. 10.1016/j.clinthera.2005.07.010, 16154480.
63. Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich ) 2004, 6(10):569-577.
64. Brachmann J, Ansari A, Mahla G, Handrock R, Klebs S. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv Ther 2008, 25(5):399-411. 10.1007/s12325-008-0054-6, 18465097.
65. Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2010, 24:587-604.
66. Chrysant SG, Lee J, Melino M, Karki S, Heyrman R. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens 2010, 24(11):730-738. 10.1038/jhh.2010.5, 2963900, 20164847.
67. Hasebe N, Kikuchi K. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005, 23(2):445-453. 10.1097/00004872-200502000-00028, 15662234.
68. Smith TR, Philipp T, Vaisse B, Bakris GL, Wernsing M, Yen J, Glazer R. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich ) 2007, 9(5):355-364.
69. European Medicines Agency List of authorised medicines for hypertension. 2011, Available from: European Medicines Agency. 2011, European Medicines Agency.
70. Burnier M. Telmisartan: a different angiotensin II receptor blocker protecting a different population?. J Int Med Res 2009, 37(6):1662-1679.
71. Song JC, White CM. Olmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertension. Formulary 2001, 35:487-499.
72. Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005, 25(1):41-46.
73. Wienen W, Entzeroth M, an Meel JCA. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 2000, 18:127-154.
74. Jugdutt BI. Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clin Interv Aging 2010, 5:403-416. 2998248, 21152242.
75. Tuck ML. Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system. Curr Hypertens Rep 2005, 7(4):240-243. 10.1007/s11906-005-0019-y, 16061040.
76. Galzerano D, Capogrosso C, Di MS, Galzerano A, Paparello P, Lama D, Gaudio C. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag 2010, 6:113-133. 2860444, 20448797.
77. Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J 2011, 32(22):2739-2747. 10.1093/eurheartj/ehr253, 3214724, 21951628.
78. Cao Z, Cooper ME. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes. Acta Diabetol 2011,
79. Azilsartan Medoxomil Prescribing Information. 2012,
80. Ding PY, Chu KM, Chiang HT, Shu KH. A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients. Int J Clin Pract Suppl 2004, 145:16-22.
81. Lacourciere Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004, 9(4):203-210. 10.1097/00126097-200408000-00005, 15311147.
82. Mallion JM, Baguet JP, Siche JP, Tremel F, De GR. Cardiac and vascular remodelling: effect of antihypertensive agents. J Hum Hypertens 1999, 13(Suppl 1):S35-S41.
83. Nishimura T, Hashimoto J, Ohkubo T, Kikuya M, Metoki H, Asayama K, Totsune K, Imai Y. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Clin Exp Hypertens 2005, 27(6):477-489. 10.1081/CEH-200067668, 16081340.
84. Sasaki T, Noda Y, Yasuoka Y, Irino H, Abe H, Adachi H, Hattori S, Kitada H, Morisawa D, Miyatake K. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome. Hypertens Res 2008, 31(5):921-929. 10.1291/hypres.31.921, 18712048.
85. Smith DH, Cramer MJ, Neutel JM, Hettiarachchi R, Koval S. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003, 8(3):111-117. 10.1097/00126097-200306000-00004, 12900588.
86. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004, 17(4):347-353. 10.1016/j.amjhyper.2004.02.016, 15062889.
87. Parati G, Schumacher H, Bilo G, Mancia G. Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database. J Hypertens 2010, 28(11):2177-2183. 10.1097/HJH.0b013e32833e1150, 20811294.
88. Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000, 16(9):1123-1132.
89. Sharma AM, Hollander A, Koster J. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol 2005, 63(4):250-257.
90. Lacourciere Y, Tytus R, O'Keefe D, Lenis J, Orchard R, Martin K. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens 2001, 15(11):763-770. 10.1038/sj.jhh.1001267, 11687919.
91. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001, 23(6):833-850. 10.1016/S0149-2918(01)80072-2, 11440284.
92. Neutel JM, Littlejohn TW, Chrysant SG, Singh A. Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens Res 2005, 28(7):555-563. 10.1291/hypres.28.555, 16335883.
93. Sharma AM, Davidson J, Koval S, Lacourciere Y. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol 2007, 6:28. 10.1186/1475-2840-6-28, 2077861, 17910747.
94. White WB, Davidai G, Schumacher H. Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension. J Hum Hypertens 2009, 23(12):817-825. 10.1038/jhh.2009.28, 19357698.
95. Littlejohn TW, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R, Oigman W. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich ) 2009, 11(4):207-213.
96. Sharma A, Bagchi A, Kinagi SB, Sharma YK, Baliga VP, Bollmall C. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther 2007, 29(12):2667-2676. 10.1016/j.clinthera.2007.12.017, 18201582.
97. Lacourciere Y, Gil-Extremera B, Mueller O, Byrne M, Williams L. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003, 57(4):273-279.
98. Lacourciere Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin Ther 2005, 27(11):1795-1805. 10.1016/j.clinthera.2005.11.014, 16368450.
99. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351(19):1952-1961. 10.1056/NEJMoa042274, 15516696.
100. Abe M, Okada K, Maruyama T, Matsumoto S, Matsumoto K. Blood pressure-lowering and antiproteinuric effect of switching from high-dose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease. Int J Clin Pharmacol Ther 2010, 48(3):206-213.
101. Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl 2008, 1:32-40.
102. Abe M, Okada K, Matsumoto K. Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide. Expet Opin Drug Metabol Toxicol 2009, 5(10):1285-1303.
103. Black HR, Bailey J, Zappe D, Samuel R. Valsartan: more than a decade of experience. Drugs 2009, 69(17):2393-2414. 10.2165/11319460-000000000-00000, 19911855.
104. Neutel JM, Franklin SS, Bhaumik A, Lapuerta P, Oparil S. Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension. Clin Exp Hypertens 2009, 31(7):572-584. 10.3109/10641960902929420, 19886855.
105. White WB, Littlejohn TW, Majul CR, Oigman W, Olvera R, Seeber M, Schumacher H, Mancia G. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Press Monit 2010, 15(4):205-212. 10.1097/MBP.0b013e32833c5722, 20613496.
106. Guthrie RM, Dahlof B, Jamerson KA, Olvera R, Seeber M, Schumacher H, Oigman W. Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients. Curr Med Res Opin 2011, 27(10):1995-2008. 10.1185/03007995.2011.616490, 21905967.
107. Sharma AM, Bakris G, Neutel JM, Littlejohn TW, Kobe M, Ting N, Ley L. Single-Pill Combination of Telmisartan/Amlodipine vs Amlodipine Monotherapy in Diabetic Hypertensive Patients: an 8-week randomised, parallel group, double blind trial. Clin Ther 2011,
108. Kidney Disease Outcomes Quality Initiative (K/DOQI) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43(5 Suppl 1):S1-S290. Kidney Disease Outcomes Quality Initiative (K/DOQI).
109. Matsui Y, Eguchi K, Ishikawa J, Shimada K, Kario K. Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker. Am J Hypertens 2011, 24(4):466-473. 10.1038/ajh.2010.240, 21164498.
110. Bakris GL, Sarafidis PA, Weir MR, Dahlof B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375(9721):1173-1181. 10.1016/S0140-6736(09)62100-0, 20170948.
111. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359(23):2417-2428. 10.1056/NEJMoa0806182, 19052124.
112. Jamerson KA, Bakris GL, Weber MA. 24-hour ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med 2010, 363(1):98. 10.1056/NEJMc1001410, 20592305.
113. Jamerson KA, Devereux R, Bakris GL, Dahlof B, Pitt B, Velazquez EJ, Weir M, Kelly RY, Hua TA, Hester A, Weber MA. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension 2011, 57(2):174-179. 10.1161/HYPERTENSIONAHA.110.159939, 21189401.
114. Cooper-DeHoff RM, Pacanowski MA, Pepine CJ. Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J Am Coll Cardiol 2009, 53(5 Suppl):S28-S34. 2655143, 19179214.
115. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369(9557):201-207. 10.1016/S0140-6736(07)60108-1, 17240286.
116. Martinez-Martin FJ, Rodriguez-Rosas H, Peiro-Martinez I, Soriano-Perera P, Pedrianes-Martin P, Comi-Diaz C. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Hum Hypertens 2011, 25(6):346-353. 10.1038/jhh.2010.104, 3099035, 21107432.
117. Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 2005, 90(4):449-455. 10.1113/expphysiol.2005.030080, 15890798.
118. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345(12):870-878. 10.1056/NEJMoa011489, 11565519.
119. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345(12):851-860. 10.1056/NEJMoa011303, 11565517.
120. Brenner BM, Cooper ME, de ZD, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345(12):861-869. 10.1056/NEJMoa011161, 11565518.
121. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002, 106(6):672-678. 10.1161/01.CIR.0000024416.33113.0A, 12163426.
122. Bakris G, Burgess E, Weir M, Davidai G, Koval S. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008, 74(3):364-369. 10.1038/ki.2008.204, 18496508.
123. Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011, 364(10):907-917. 10.1056/NEJMoa1007994, 21388309.
124. Galle J, Schwedhelm E, Pinnetti S, Boger RH, Wanner C. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008, 23(10):3174-3183. 10.1093/ndt/gfn230, 18450829.
125. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342(3):145-153.
126. Mann JF, Schmieder RE, Dyal L, cQueen M, Schumacher H, Pogue J, Wang X, robstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Rydén L, Yu CM, Teo KK, Yusuf S, . TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009, 151(1):1-10. TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators.
127. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372(9638):547-553. 10.1016/S0140-6736(08)61236-2, 18707986.
128. Ritz E, Schmieder RE, Pollock CA. Renal protection in diabetes: lessons from ONTARGET. Cardiovasc Diabetol 2010, 9:60. 10.1186/1475-2840-9-60, 2959007, 20920303.
129. Malacco E, Santonastaso M, Vari NA, Gargiulo A, Spagnuolo V, Bertocchi F, Palatini P. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 2004, 26(6):855-865. 10.1016/S0149-2918(04)90129-4, 15262456.